US Stock MarketDetailed Quotes

RGNX Regenxbio

Watchlist
  • 16.670
  • -0.290-1.71%
Close May 8 16:00 ET
817.54MMarket Cap-2769P/E (TTM)

About Regenxbio Company

REGENXBIO, Inc. is a clinical-stage biotechnology company, which engages in the development, commercialization, and licensing of recombinant adeno-associated virus gene therapy. Its product candidates include the NAV Technology Platform, which consists of exclusive rights to novel adeno-associated viral vectors, and therapeutic programs such as RGX-314, RGX-202, RGX-121, RGX-111, RGX-181, and RGX-381. The company was founded by Kenneth T. Mills and James M. Wilson on July 16, 2008 and is headquartered in Rockville, MD.

Company Profile

SymbolRGNX
Company NameRegenxbio
Listing DateSep 17, 2015
Issue Price22.00
Founded2008
CEOMr. Kenneth T. Mills
MarketNASDAQ
Employees344
Securities TypeOrdinary Shares
Fiscal Year Ends12-31
Address9804 Medical Center Drive
CityRockville
ProvinceMaryland
CountryUnited States of America
Zip Code20850
Phone1-240-552-8181
Websitehttp://www.regenxbio.com

Company Executives

  • Name
  • Position
  • Salary
  • Kenneth T. Mills
  • President, Chief Executive Officer and Director
  • 5.92M
  • Stephen Pakola, M.D.
  • Executive Vice President and Chief Medical Officer
  • 3.31M
  • Dr. Olivier Danos, PhD
  • Executive Vice President and Chief Scientific Officer
  • 2.99M
  • Vittal Vasista
  • Executive Vice President, Chief Financial Officer and Principal Accounting Officer
  • 2.62M
  • Patrick J. Christmas
  • Executive Vice President and Chief Legal Officer
  • 1.83M
  • Curran Simpson
  • Executive Vice President and Chief Operating Officer
  • 2.95M
  • Allan M. Fox
  • Chairman of the Board
  • 354.98K
  • Dr. Alexandra Glucksmann, PhD
  • Independent Director
  • 327.48K
  • Daniel Tasse
  • Independent Director
  • 334.98K
  • Dr. Jean Bennett, M.D.,Pd.D
  • Independent Director
  • 324.98K
  • Jennifer Zachary
  • Independent Director
  • 329.98K
  • Dr. David C. Stump,M.D.
  • Independent Director
  • 339.98K
  • Dr. Argeris N. Karabelas, PhD
  • Lead Independent Director
  • 352.48K
  • George V. Migausky
  • Independent Director
  • 339.98K

Analysis

Analyst Rating

No Data

Price Target

No Data

Heat List
US
Overall
Symbol
Latest Price
%Chg